New shot aims to slash heart attack risk by taming cholesterol
NCT ID NCT04951856
Summary
This study is testing if a cholesterol-lowering injection called evolocumab works better than standard care for people who have just had a serious heart attack. It involves over 2,100 patients across Europe who will receive either the new injection or follow current treatment guidelines. The main goal is to see which approach helps patients reach and maintain very low 'bad' cholesterol levels one year after their heart attack.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSTEMI - NON-ST SEGMENT ELEVATION MI are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ACTION Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière (APHP), UPMC
Paris, 75013, France
Conditions
Explore the condition pages connected to this study.